Wogonin
CAS 632-85-9
Wogonin (CAS 632-85-9) is a pharmaceutical compound with 6 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 47589.184482758625 nM | 58 | - |
| - | IC50 | 22372.919285714284 nM | 41 | - |
| - | Potency | 28448.8 nM | 15 | - |
| - | MIC | 116.66666666666667 ug.mL-1 | 3 | - |
| - | Ki | 2785.87 nM | 2 | - |
| - | IC50 | 4 ug.mL-1 | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Wogonin used for in pharmaceutical contexts?
Wogonin (CAS 632-85-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Wogonin?
No adverse-event association or SIDER side-effect rows are rendered for Wogonin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Wogonin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Wogonin with EU status "permitted".
What clinical phase is Wogonin in?
No phase 1-4 clinical development badge is rendered for Wogonin because the matched compound identifier rows do not contain a max-phase value.